Article Text

Download PDFPDF

1095 CD51 as a newly identified immunomodulatory protein: investigating expression and function on CD8 T cells
  1. Solhwi Lee1 and
  2. Se Jin Im2
  1. 1Sungkyunkwan University School of Medicine, Suwon-si, Republic of Korea
  2. 2Graduate School of Basic Medical Science, Sungkyunkwan University School of Medicine, Suwon-si, Republic of Korea
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background T cell responses are regulated by co-stimulatory and inhibitory receptors along with T cell receptor- and cytokine-mediated signals. CD51, also known as alpha v integrin (ITGAV), is a transmembrane glycoprotein of the integrin family involved in cell adhesion, migration, tumorigenesis, and other cellular functions.1–7 However, the expression and function of CD51 in CD8 T cells during activation have not been previously examined. Therefore, this study aimed to investigate the expression and role of CD51 specifically in CD8 T cells.

Methods Analysis of RNA-sequencing data from exhausted CD8 T cells in mice with chronic lymphocytic choriomeningitis virus (LCMV) or B16F10 tumor models revealed high expression of Itgav (encoding CD51) in exhausted CD8 T cells from both mouse models. Itgav expression increased as CD8 T cells underwent terminal differentiation, similar to the expression pattern of Pdcd1. To assess CD51 expression during T cell activation, we stimulated total splenocytes with anti-CD3 antibodies. Additionally, we examined CD51 expression in exhausted CD8 T cells using four murine models: chronic LCMV infection, B16F10 melanoma, CT26 colon carcinoma, and acute graft-versus-host disease (GvHD). To investigate the role of CD51 in CD8 T cell activation, we employed CD51-blocking antibodies in in vitro activation and utilized CRISPR-mediated knockdown (KD) of CD51 in P14 CD8 T cells in vivo.

Results in vitro T cell activation revealed delayed but subsequent upregulation of CD51 expression during CD8 T cell division. Moreover, high CD51 expression was observed in exhausted CD8 T cells from cases of chronic LCMV infection, B16F10 melanoma, CT26 colon carcinoma, and acute GvHD. Furthermore, CD51 expression increased as the cells became more differentiated. CRISPR-mediated knockdown of CD51 resulted in decreased numbers of virus-specific CD8 T cells during LCMV infection, while maintaining granzyme B expression and cytokine production. Blockade of CD51 using antibodies significantly restrained T cell proliferation while preserving CD8 T cell activity.

Conclusions Our study demonstrates the upregulation of CD51 and its impact on CD8 T cell proliferation. Moreover, we identified that CD51-blocking antibodies effectively inhibit T cell activation. These findings highlight CD51 as a newly identified immunomodulatory protein with potential for enhancing the effectiveness of anticancer treatments in tumor models and mitigating immunopathological damage in autoimmune disorders and graft-versus-host diseases.

Acknowledgements This study was supported by a National Research Foundation of Korea (NRF) grant (S.J.I.) funded by the Korean government (MSIT) (RS-2023–00211426) and by a National Cancer Center Grant (NCC203186) (S.J.I.). This research was also supported by Korea Basic Science Institute (National Research Facilities and Equipment Center) grant funded by the Ministry of Education (2020R1A6C101A191).


  1. L Seguin, JS Desgrosellier, SM Weis, DA Cheresh. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance, Trends Cell Biol. 2015;25:234–240.

  2. H Wang, H Chen, Z Jiang, Y Lin, X Wang, J Xiang, J Peng. Integrin subunit alpha V promotes growth, migration, and invasion of gastric cancer cells. Pathol. Res. Pract. 2019;215:152531.

  3. J Waisberg, L De Souza Viana, RJ Affonso Junior, SR Silva, MV Denadai, FB Margeotto, CS De Souza, D Matos. Overexpression of the ITGAV gene is associated with progression and spread of colorectal cancer. Anticancer Res. 2014;34:5599–5607.

  4. MA Sims, SD Field, MR Barnes, N Shaikh, K Ellington, KE Murphy, N Spurr, DA Campbell. Cloning and characterisation of ITGAV, the genomic sequence for human cell adhesion protein (vitronectin) receptor alpha subunit, CD51, Cytogenet. Cell Genet. 2000;89:268–271.

  5. D Bouvard, C Brakebusch, E Gustafsson, A Aszodi, T Bengtsson, A Berna, R Fassler. Functional consequences of integrin gene mutations in mice, Circ. Res. 2001;89:211–223.

  6. JA Nemeth, MT Nakada, M Trikha, Z Lang, MS Gordon, GC Jayson, R Corringham, U Prabhakar, HM Davis, RA Beckman. Alpha-v integrins as therapeutic targets in oncology, Cancer Invest. 2007;25:632–646.

  7. K Horioka, K Ohuchida, M Sada, B Zheng, T Moriyama, H Fujita, T Manabe, T Ohtsuka, M Shimamoto, T Miyazaki, K Mizumoto, Y Oda, M Nakamura. Suppression of CD51 in pancreatic stellate cells inhibits tumor growth by reducing stroma and altering tumor-stromal interaction in pancreatic cancer. Int. J. Oncol. 2016;48:1499–1508.

Ethics Approval All experiments were conducted in accordance with the Institutional Animal Care and Use Committee guidelines of Sungkyunkwan University School of Medicine.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.